Clinical trials: Old Age; Atrophy

Duchenne Muscular Dystrophy

Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy

• Completed
• Age: 2 to 5 years
• Phase 2
• Results posted

This is a Phase 2, multiple-dose, open-label study evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ataluren in participants aged ≥2 to <5 years old with Duchenne muscular dystrophy (DMD) caused by a…

Trial name

NCT02819557

Testing

Ataluren

Where

6 sites in United States

Volunteers

14 people

Sponsor

PTC Therapeutics